Literature DB >> 10500494

Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.

M Bonfanti1, E La Valle, J M Fernandez Sousa Faro, G Faircloth, G Caretti, R Mantovani, M D'Incalci.   

Abstract

Ecteinascidin-743 (ET-743) is a tetrahydroisoquinoline alkaloid isolated from Ecteinascidia turbinata, a tunicate growing in mangrove roots in Caribbean. It has been shown to bind in the minor groove of DNA forming covalent adducts by reaction of the N2 of guanine with the carbinolamine moiety. We investigated ET-743 ability to inhibit the binding of different transcription factors to their consensus sequences by using gel shift assays. We have selected three types of factors: (i) oncogene products such as MYC, c-MYB and Maf; (ii) transcriptional activators regulated during the cell cycle as E2F and SRF; and (iii) general transcription factors such as TATA binding protein (TBP), Sp1 and NF-Y. We observed no inhibition of the binding of Sp1, Maf, MYB and MYC. Inhibition of DNA binding was observed for TBP, E2F, SRF at ET-743 concentrations ranging from 50 to 300 microM. The inhibition of binding of NF-Y occurs at even lower concentrations (i.e. 10-30 microM) when the recombinant subunits of NF-Y are preincubated with the drug, indicating that the inhibition of NF-Y binding does not require previous ET-743 DNA binding. Since NF-Y is a trimer containing two subunits with high resemblance to histones H2B and H2A, we have investigated the effect of ET-743 on nucleosome reconstitution. ET-743 caused a decrease of the nucleosomal band at 100 nM, with the complete disappearance of the band at 3-10 microM. These data suggest that the mode of action of this novel anticancer drug is related to its ability to modify the interaction between some DNA binding proteins and DNA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500494

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  15 in total

1.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Authors:  M Minuzzo; S Marchini; M Broggini; G Faircloth; M D'Incalci; R Mantovani
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Activity of trabectidin in desmoplastic small round cell tumor.

Authors:  Ana López-González; Blanca Cantos; Eva Tejerina; Mariano Provencio
Journal:  Med Oncol       Date:  2010-10-07       Impact factor: 3.064

Review 3.  Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

Authors:  V H Le; M Inai; R M Williams; T Kan
Journal:  Nat Prod Rep       Date:  2015-02       Impact factor: 13.423

Review 4.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

5.  Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.

Authors:  S Jin; B Gorfajn; G Faircloth; K W Scotto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

6.  Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

Authors:  Chun-Nam Lok; Alexander J Lang; Shelagh E L Mirski; Susan P C Cole
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

7.  Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).

Authors:  E Erba; D Bergamaschi; L Bassano; S Ronzoni; G Di Liberti; I Muradore; S Vignati; G Faircloth; J Jimeno; M D'Incalci
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

Review 8.  Trabectedin in soft tissue sarcomas.

Authors:  Bradley J Petek; Elizabeth T Loggers; Seth M Pollack; Robin L Jones
Journal:  Mar Drugs       Date:  2015-02-12       Impact factor: 5.118

9.  DNA and the chromosome - varied targets for chemotherapy.

Authors:  Stephanie M Nelson; Lynnette R Ferguson; William A Denny
Journal:  Cell Chromosome       Date:  2004-05-24

Review 10.  Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts.

Authors:  Gaëlle Savreux-Lenglet; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Int J Mol Sci       Date:  2015-11-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.